Ovarian Cancer Treatment Market Size, Share, Opportunities, COVID 19 Impact, And Trends By Diagnosis (Blood Tests, Imaging Tests, Laparoscopy, Colonoscopy, Others), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Hormone Therapy, Clinical Trials), And By Geography - Forecasts From 2019 To 2024

Published:  May 2021 Report Code: KSI061612669 Pages: 120

The ovarian cancer treatment market is projected to grow at a CAGR of 7.02% to reach US$2.505 billion by 2024.

The ovarian cancer treatment market is expected to grow at a fast pace during the forecast period due to the growing incidence of ovarian cancer among women worldwide. According to the American Cancer Society, around 22,530 new cases of ovarian cancer will be diagnosed in 2019 and around 13,980 deaths are likely to occur in the same year. Region-wise, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions. The growing number of clinical trials have improved the chances of new innovations for targeted cancer treatment, emanating the market growth during the forecast period. Growing awareness among women has further led to early diagnosis, further leading to the treatment of ovarian cancer at an early stage, when diagnosed, thus, improving the survival rate of the patients. Currently available treatments include surgery, chemotherapy, radiation therapy, and hormonal therapy.

DRIVERS
Rising ovarian cancer incidence
Growing number of clinical trials for new innovations
Increasing health expenditure

RESTRAINTS
High cost of cancer treatment

INDUSTRY UPDATE
According to the Biospectrum news on 21st June 2019, the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) entered into a collaboration with AstraZeneca for enhancing the quality in cancer for people suffering from advanced ovarian cancer.
Predictive Oncology, previously known as Precision Therapeutics, in April 2019, announced that it has entered into a collaboration with Helomics and Viome to study the link between the gut microbiome and ovarian cancer.

Major industry players profiled as part of the report are Sotio (Member of PPF Group), Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, TESARO, Inc., Clovis Oncology, AbbVie Inc., Oasmia Pharmaceutical AB, ImmunoGen Inc., and Boehringer Ingelheim GmbH.

Ovarian Cancer Treatment Market Scope:

Report Metric Details
 Market size value in 2024  US$2.505 billion
 Growth Rate  CAGR of 7.02% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Diagnosis, Treatment, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered Sotio (Member of PPF Group), Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, TESARO, Inc., Clovis Oncology, AbbVie Inc., Oasmia Pharmaceutical AB, ImmunoGen Inc., Boehringer Ingelheim GmbH
 Customization scope  Free report customization with purchase

 

Segmentation

The ovarian cancer treatment market has been analyzed through the following segments:

By Diagnosis
Blood Tests
Imaging Tests
Laparoscopy
Colonoscopy
Others

By Treatment
Surgery
Radiation Therapy
Chemotherapy
Hormone Therapy
Clinical Trials

By Geography

North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others


Frequently Asked Questions (FAQs)

Q1. What will be the ovarian cancer treatment market size by 2024?
A1. The ovarian cancer treatment market is projected to reach a total market size of US$2.505 billion by 2024.

Q2. Who are the major players in the ovarian cancer treatment market?
A2. Major industry players profiled as part of the report are Sotio (Member of PPF Group), Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, TESARO, Inc., Clovis Oncology, and among others.

Q3. What are the growth prospects for the ovarian cancer treatment market?
A3. The global ovarian cancer treatment market is projected to grow at a CAGR of 7.02% during the forecast period.

Q4. Which region holds the largest market share in the ovarian cancer treatment market?
A4. North America is expected to hold the highest share in the ovarian cancer treatment market owing to the highest health spending of the United States among all the developed regions.

Q5. What factors are anticipated to drive the ovarian cancer treatment market growth?
A5. The ovarian cancer treatment market is expected to grow at a fast pace during the forecast period due to the growing incidence of ovarian cancer among women worldwide.

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By region
4.6. Product Pipeline
4.7. Innovations
5. OVARIAN CANCER TREATMENT MARKET BY DIAGNOSIS
5.1. Blood Tests
5.2. Imaging Tests
5.3. Laparoscopy
5.4. Colonoscopy
5.5. Others
6. OVARIAN CANCER TREATMENT MARKET BY TREATMENT
6.1. Surgery
6.2. Radiation Therapy
6.3. Chemotherapy
6.4. Hormone Therapy
6.5. Clinical Trials
7. OVARIAN CANCER TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Sotio (Member of PPF Group)
9.2. Pfizer Inc.
9.3. AstraZeneca
9.4. F. Hoffmann-La Roche Ltd
9.5. TESARO, Inc.
9.6. Clovis Oncology
9.7. AbbVie Inc.
9.8. Oasmia Pharmaceutical AB
9.9. ImmunoGen Inc.
9.10. Boehringer Ingelheim GmbH
LIST OF FIGURES
LIST OF TABLES

Sotio (Member of PPF Group)
Pfizer Inc.
AstraZeneca
F. Hoffmann-La Roche Ltd
TESARO, Inc.
Clovis Oncology
AbbVie Inc.
Oasmia Pharmaceutical AB
ImmunoGen Inc.
Boehringer Ingelheim GmbH

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us